The OxyVita Product

Our product, OxyVita, is a novel "next" generation oxygen carrier, which we believe will have unrestricted application in the future for human and animal use in all situations requiring oxygen delivery to the body. The product was originally developed and patented by a group of scientists at the University of Maryland, led by Prof. E. Bucci, and has many years of scientific experiments supporting it.

The zero-linked polymerization technology allows for the construction of a structurally stable polymer with a predefined size, containing hemoglobin molecules only. All animal studies performed to date showed only beneficial results on the application of the product for animal use. Based on the performed analytical testing and animal studies, OxyVita eliminates extravasation and associated pressor response, maximizes intravascular retention time, eliminates potential toxicity from residual linking agents, and can use bovine, human or any mammalian hemoglobin as the raw material.

No side effects have been discovered to date with regard to the application of this product. Our oxygen carrier aims to revolutionize blood science, not only as a blood substitute in trauma patients, but also as a novel oxygen carrier and a novel drug delivery system. The OxyVita product has the potential to reform the whole approach to the problem of transplant organ storage as well.